Opendata, web and dolomites

RIVELIN-CLO SIGNED

The Ultimate Therapy for the Oral Lichen Planus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RIVELIN-CLO project word cloud

Explore the words cloud of the RIVELIN-CLO project. It provides you a very rough idea of what is the project "RIVELIN-CLO" about.

struggle    combined    lives       saliva    mucosal    clinics    causing    cure    launching    lack    toxicity    share    lichen    living    staff    erosive    approved    correct    generate    ways    damage    markets    suffering    involve    occlusion    gather    lesions    kept    burning    spread    mucosa    hospitals    trials    international    therapeutic    bystander    afyx    dosing    ongoing    rivelin    people    reg    planus    guarantee    incorporating    danish    lower    drug    electrospinning    daily    sensations    clo    symptoms    10m    topical    options    adherence    precancerous    normal    treat    clobetasol    oral    goals    time    potentially    undesired    ip    clinical    company    painful    therapeutics    22    perspectives    employees    commercial    generating    innovative    alleviation    chronic    tissues    first    2014    6m    patients    minimization    exclusively    usa    systemic    disorder    primary    ultimately    prevented    2h    venture    financial    efficacy    olp    market    patch    worldwide    launch    founded    lesion    iib    revenues    treatment    self    immune    corticosteroids    diseases    84m    chance   

Project "RIVELIN-CLO" data sheet

The following table provides information about the project.

Coordinator
AFYX THERAPEUTICS A/S 

Organization address
address: LERGRAVSVEJ 57, 2TV.
city: COPENHAGEN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AFYX THERAPEUTICS A/S DK (COPENHAGEN) coordinator 50˙000.00

Map

 Project objective

Oral lichen planus (OLP) is an immune-related disorder affecting 84M people worldwide (10M in EU and USA). OLP is a chronic condition which can ultimately lead to precancerous lesions, while patients suffering from it may struggle daily with painful and/or burning sensations in the oral mucosa, being thus kept from living their normal lives. Since there is no approved cure for OLP, the primary goals of its treatment are the alleviation of symptoms and the minimization of mucosal damage from erosive lesions. Current therapeutic options involve the use of topical corticosteroids (typically Clobetasol). However, the ways of use available in the market show lack of adherence to the mucosa and there is a high chance that the product is spread to other areas (which results in reduced efficacy and potentially causing undesired topical and systemic side effects). Our Danish company AFYX Therapeutics A/S was founded in 2014 with the aim to develop innovative approaches to treat mucosal diseases such as OLP. We have developed our first product incorporating an innovative technology (using an electrospinning process): the RIVELIN®-CLO patch. It’s the first to have been developed exclusively for the treatment of OLP, and its unique properties include self-adherence to the oral tissues (2h of topical drug application); occlusion of the lesion; lower bystander toxicity (Clobetasol is prevented from being spread by saliva) and the correct dosing every time. Clinical Phase IIb trials of the patch are ongoing with clinics and hospitals across EU and US and through this project we aim to guarantee that RIVELIN®-CLO is a success from a technical, commercial and financial perspectives, before launching it to the international markets. Five years after market launch, we expect to gather 7% of the EU and US combined OLP treatment market share, generating €22.6M revenues to our company and increasing our staff to 40 employees and generate new IP to venture new markets with our technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIVELIN-CLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIVELIN-CLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More